Decitabine enhances anti-CD33 monoclonal antibody BI 836858–mediated natural killer ADCC against AML blasts
2016; Elsevier BV; Volume: 127; Issue: 23 Linguagem: Inglês
10.1182/blood-2015-11-680546
ISSN1528-0020
AutoresSumithira Vasu, Shun He, Carolyn Cheney, Bhavani Gopalakrishnan, Rajeswaran Mani, Gerard Lozanski, Xiaokui Mo, Veronica Groh, Susan P. Whitman, Renate Konopitzky, Christian Kössl, Donna Bucci, David Lucas, Jianhua Yu, Michael A. Caligiuri, William Blum, Paul J. Adam, Eric Borges, Bjoern Rueter, Karl‐Heinz Heider, Guido Marcucci, Natarajan Muthusamy,
Tópico(s)T-cell and B-cell Immunology
ResumoKey Points BI 836858, an Fc-engineered anti-CD33 antibody, mediates autologous and allogeneic NK cell–mediated ADCC. Decitabine increases ligands for activating NK receptors potentiating BI 836858 activity, providing a rationale for combination therapy.
Referência(s)